Company / Depreciation & Amortization
Vistagen Therapeutics, Inc. Depreciation & Amortization History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$153.5K
FY2023
5-year range
$53.5K / $153.5K
FY2019-FY2023
Trend
+30.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 5 consecutive years, from $33,800 in FY2014 to $153,500 in FY2023.
Based on SEC 10-K filings.
$153,500 in FY2023 with a 5-year CAGR of +22.8%.
Increased from $103,100 to $153,500 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +22.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vistagen Therapeutics, Inc.'s depreciation & amortization has grown for 5 consecutive years.
- 5-year CAGR of +22.8%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 30.5% year-over-year.
- Lowest depreciation & amortization in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $153.5K | +30.5% |
| FY2022 | $117.6K | +14.1% |
| FY2021 | $103.1K | +87.8% |
| FY2018 | $54.9K | +2.6% |
| FY2017 | $53.5K | +58.3% |
| FY2014 | $33.8K | -25.9% |
| FY2012 | $45.6K | +0.7% |
| FY2011 | $45.3K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026